Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.30 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20495193 | 1.00 | CES2 (0.42) | CES2CES1PDPK1APPMME | |
| SCHEMBL17165350 | 0.84 | PSEN1 (0.36) | APPALDH1A1S1PR1S1PR3 | |
| SCHEMBL5702253 | 0.84 | SHBG (0.46) | SHBG | |
| SCHEMBL19555328 | 0.84 | PSEN1 (0.36) | APPALDH1A1S1PR1S1PR3 | |
| SCHEMBL6182737 | 0.82 | ALDH1A1 (0.43) | AKR1C3AKR1C2ALDH1A1 | |
| SCHEMBL12492053 | 0.82 | KDM1A (0.33) | — | |
| SCHEMBL28165420 | 0.77 | CES2 (0.43) | CES2CES1PDPK1MMEAKR1C3 | |
| SCHEMBL1028130 | 0.76 | IDO1 (0.38) | CES2CES1ALDH1A1 | |
| SCHEMBL30124887 | 0.75 | CES2 (0.50) | CES2CES1PDPK1APPMME | |
| SCHEMBL998053 | 0.75 | CES2 (0.42) | CES2CES1PDPK1MMEAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223335-A1 | A METHOD FOR PREPARING (1S)-2-CHLORO-1-(3,4-DIFLUOROPHENYL) ETHANOL | AARTI PHARMALABS LIMITED (IN) | 2023-11-23 | — | — | WO | claimed |
| WO-2023223335-A1 | A METHOD FOR PREPARING (1S)-2-CHLORO-1-(3,4-DIFLUOROPHENYL) ETHANOL | AARTI PHARMALABS LIMITED (IN) | 2023-11-23 | — | — | WO | disclosed |
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-3303267-A2 | HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR | California Institute of Technology (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016191612-A2 | HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-12-01 | — | — | WO | disclosed |
| EP-2588441-A2 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | Actavis Group Ptc Ehf (IS) | 2013-05-08 | — | — | EP | disclosed |
| EP-2560939-A2 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | Actavis Group Ptc Ehf (IS) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012001531-A2 | NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR | ACTAVIS GROUP PTC EHF (IS) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011132083-A2 | NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2011-10-27 | — | — | WO | disclosed |
| EP-2049462-A1 | CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| EP-1912976-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1904477-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008018822-A1 | CHEMICAL PROCESS FOR PREPARATION OF AROMATIC CYCLOPROPANE ESTERS AND AMIDES | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007009906-A1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOL DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167078-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | CES2 3468/4885CES1 1403/4885PDPK1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.